Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Oncol.

Sec. Thoracic Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1619250

Pemetrexed-Induced Pseudocellulitis: a rare adverse effect to be recognized for improved management

Provisionally accepted
Emma  ProuxEmma ProuxJeanne  ChenJeanne ChenCaroline  BonhommeCaroline BonhommePierre  PottierPierre PottierMarie  PIROTHMarie PIROTH*
  • Centre Hospitalier Universitaire (CHU) de Nantes, Nantes, France

The final, formatted version of the article will be published soon.

Pseudocellulitis, a non-infectious inflammatory reaction mimicking infectious cellulitis is a rare and often underrecognized adverse reaction to pemetrexed, frequently diagnosed late and leading to inappropriate treatments, particularly unnecessary antibiotic use. Through the presentation of a new case and a literature review conducted using Scopus and PubMed, we aim to clarify its clinical presentation and management. We report a new case of pemetrexed-induced pseudocellulitis (PIP), initially misdiagnosed and treated unnecessarily with multiple antibiotics. Following the correct diagnosis, the patient was successfully treated with both oral and topical corticosteroids. Pemetrexed had to be discontinued. PIP clinically mimics cellulitis, presenting unilaterally or bilaterally, sometimes accompanied by fever and inflammatory syndrome. Its onset is variable, occurring either after the initial pemetrexed administration or following subsequent cycles, with no clear dose dependency. Skin biopsy is not essential for diagnosis. Management typically involves local and/or systemic corticosteroids. Discontinuation of pemetrexed should be evaluated on a case-by-case basis and is not always necessary. Improved recognition of this condition is essential to avoid unnecessary interventions, enhance patient care, and prevent long-term complications due to prolonged inflammation.

Keywords: Pemetrexed-Induced-Pseudocellulitis, Pseudocellulitis, Cellulitis, pemetrexed, Anti-folate

Received: 27 Apr 2025; Accepted: 25 Sep 2025.

Copyright: © 2025 Proux, Chen, Bonhomme, Pottier and PIROTH. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Marie PIROTH, mariepiroth@hotmail.fr

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.